All News Exelixis, Inc.

Equities

EXEL

US30161Q1040

Real-time Estimate Cboe BZX Other stock markets 09:47:01 2024-04-25 am EDT			5-day change	1st Jan Change
23.54 ^USD	-0.74%		+5.20%	-1.38%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Apr. 11	Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024	Apr. 16	BU
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25	Apr. 11	MT
Jacqueline Wright Notifies Exelixis, Inc. of Her Decision Not to Stand for Re-Election to the Board of Directors	Mar. 29	CI
Transcript : Exelixis, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM	Mar. 13
Transcript : Exelixis, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 09:20 AM	Mar. 12
Transcript : Exelixis, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	Mar. 05
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March	Feb. 27	BU
BioInvent International AB Year-end report January 1, December 31, 2023	Feb. 23	AQ
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing	Feb. 22	MT
BioInvent International AB Year-end report January 1 – December 31, 2023	Feb. 22	AQ
Transcript : Exelixis, Inc. Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference, Feb-13-2024 12:40 PM	Feb. 13
Transcript : Exelixis, Inc. Presents at Guggenheim Healthcare Talks\| 6th Annual Biotechnology Conference, Feb-08-2024 09:00 AM	Feb. 08
RBC Raises Price Target on Exelixis to $28 From $26, Keeps Outperform Rating	Feb. 07	MT
Exelixis Swings to Earnings in Fiscal Q4 as Sales Increase; 2024 Revenue Guidance Set	Feb. 06	MT
Transcript : Exelixis, Inc., Q4 2023 Earnings Call, Feb 06, 2024	Feb. 06
Exelixis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06	CI
Exelixis: Q4 Earnings Snapshot	Feb. 06	AQ
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024	Feb. 06	CI
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update	Feb. 06	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Exelixis, Inc.

Equities

EXEL

US30161Q1040

All News

Filters